{"id":2288,"date":"2017-07-07T00:00:00","date_gmt":"2017-07-07T00:00:00","guid":{"rendered":"http:\/\/www.pharma-mkting.comindex.php\/2017\/07\/07\/pinup070717\/"},"modified":"2019-02-06T02:14:44","modified_gmt":"2019-02-06T02:14:44","slug":"pinup070717","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/news\/pinup070717\/","title":{"rendered":"PinUp: Influencing the Cancer Treatment “Gray” Zone at FDA and Online, more…"},"content":{"rendered":"

Pharma Industry News Update<\/b>: 7 July 2017<\/p>\n\n

To Influence Cancer Treatment “Gray Zone”
92% of Experts Speaking at FDA Cancer Drug Panels Are Paid by Pharma<\/p>\n

<\/p>\n

[From www.statnews.com] A new analysis finds that many experts who spoke before the FDA committee that reviews cancer drugs held financial conflicts of interest with the pharmaceutical industry.<\/p>\n

Specifically, the analysis identified 38 experts and found that 92 percent – or 35 of them – had received industry payments. And 47 percent – or 18 experts – had documented payments from the specific drug makers that were hoping to win an FDA approval. Moreover, there were significant correlations found between the number of published articles, total citations and industry payments<\/p>\n

“As you go into the rarified quarters of academic oncology, you see experts whose influence is tremendous,” said Dr. Vinay Prasad, an assistant professor of medicine at the Oregon Health and Sciences University, who recently co-authored a separate analysis that found nearly 80 percent of U.S. hematologist-oncologists who use Twitter have financial conflicts of interest.<\/p>\n

“But so many oncology decisions are made in a gray zone, not black-and-white data, and these are the people in a position to determine shades of gray area. And this is why it’s so problematic that these people are conflicted. An expert may be the only person in the room at an FDA meeting who has treated 5,000 lung patients. And all of us follow their lead.”<\/p>\n

More here…<\/a><\/p>\n

Further Reading:<\/p>\n